Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.
Eurofins Scientific Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€119.94|
|52 Week High||€61.32|
|52 Week Low||€127.68|
|1 Month Change||1.03%|
|3 Month Change||24.74%|
|1 Year Change||79.82%|
|3 Year Change||145.28%|
|5 Year Change||196.62%|
|Change since IPO||50,301.31%|
Recent News & Updates
Are Eurofins Scientific SE (EPA:ERF) Investors Paying Above The Intrinsic Value?
Today we will run through one way of estimating the intrinsic value of Eurofins Scientific SE ( EPA:ERF ) by taking the...
We Think Eurofins Scientific (EPA:ERF) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Do Eurofins Scientific's (EPA:ERF) Earnings Warrant Your Attention?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
|ERF||FR Life Sciences||FR Market|
Return vs Industry: ERF exceeded the French Life Sciences industry which returned 64.6% over the past year.
Return vs Market: ERF exceeded the French Market which returned 40.1% over the past year.
Stable Share Price: ERF is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ERF's weekly volatility (4%) has been stable over the past year.
About the Company
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as for clinical diagnostic. It provides agroscience, agro testing, assurance, biopharma, clinical diagnostics, consumer product testing, cosmetics and personal care, environment testing, food and feed testing, forensic, genomic, maritime, materials and engineering, technologies, and REACH services.
Eurofins Scientific Fundamentals Summary
|ERF fundamental statistics|
Is ERF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ERF income statement (TTM)|
|Cost of Revenue||€4.46b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||4.30|
|Net Profit Margin||12.92%|
How did ERF perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is Eurofins Scientific undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ERF (€119.94) is trading above our estimate of fair value (€83.08)
Significantly Below Fair Value: ERF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ERF is good value based on its PE Ratio (27.9x) compared to the European Life Sciences industry average (52.8x).
PE vs Market: ERF is poor value based on its PE Ratio (27.9x) compared to the French market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: ERF's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ERF is overvalued based on its PB Ratio (5.6x) compared to the XE Life Sciences industry average (5x).
How is Eurofins Scientific forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ERF's earnings are forecast to decline over the next 3 years (-6.1% per year).
Earnings vs Market: ERF's earnings are forecast to decline over the next 3 years (-6.1% per year).
High Growth Earnings: ERF's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ERF's revenue (0.2% per year) is forecast to grow slower than the French market (6.3% per year).
High Growth Revenue: ERF's revenue (0.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ERF's Return on Equity is forecast to be low in 3 years time (14.2%).
How has Eurofins Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ERF has high quality earnings.
Growing Profit Margin: ERF's current net profit margins (12.9%) are higher than last year (4%).
Past Earnings Growth Analysis
Earnings Trend: ERF's earnings have grown significantly by 36.9% per year over the past 5 years.
Accelerating Growth: ERF's earnings growth over the past year (335.4%) exceeds its 5-year average (36.9% per year).
Earnings vs Industry: ERF earnings growth over the past year (335.4%) exceeded the Life Sciences industry 79.1%.
Return on Equity
High ROE: ERF's Return on Equity (21%) is considered high.
How is Eurofins Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: ERF's short term assets (€2.4B) exceed its short term liabilities (€1.8B).
Long Term Liabilities: ERF's short term assets (€2.4B) do not cover its long term liabilities (€2.8B).
Debt to Equity History and Analysis
Debt Level: ERF's debt to equity ratio (51.6%) is considered high.
Reducing Debt: ERF's debt to equity ratio has reduced from 122.2% to 51.6% over the past 5 years.
Debt Coverage: ERF's debt is well covered by operating cash flow (70.2%).
Interest Coverage: ERF's interest payments on its debt are well covered by EBIT (12.9x coverage).
What is Eurofins Scientific current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ERF's dividend (0.57%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.28%).
High Dividend: ERF's dividend (0.57%) is low compared to the top 25% of dividend payers in the French market (3.93%).
Stability and Growth of Payments
Stable Dividend: ERF is not paying a notable dividend for the French market, therefore no need to check if payments are stable.
Growing Dividend: ERF is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: ERF is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ERF's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Gilles Martin (58 yo)
Dr. Gilles G. Martin, Ph D., serves as the Chief Executive Officer at Eurofins Scientific, Inc. Dr. Martin serves as Chief Executive Officer of Eurofins Nihon Kankyo K.K. and Eurofins Scientific Group. He...
CEO Compensation Analysis
Compensation vs Market: Gilles's total compensation ($USD1.35M) is below average for companies of similar size in the French market ($USD3.28M).
Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.
Experienced Board: ERF's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eurofins Scientific SE's employee growth, exchange listings and data sources
- Name: Eurofins Scientific SE
- Ticker: ERF
- Exchange: ENXTPA
- Founded: 1987
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: €23.005b
- Shares outstanding: 191.81m
- Website: https://www.eurofins.com
Number of Employees
- Eurofins Scientific SE
- 23 Val Fleuri
- Luxembourg City
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/24 22:54|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.